Was athenahealth's Epocrates Buy a Good Move?

Massachussetts-based athenahealth (NASDAQ: ATHN  ) just stirred things up a bit in the physician software market. The company announced Monday that it planned to buy point-of-care software provider Epocrates (UNKNOWN: EPOC.DL  ) for $293 million. That price reflects a 22% premium compared to the stock's Friday close. Was this a good move for athenahealth? Let's take a look.

Upward mobility?
One opportunity that athenahealth sees from the acquisition is in getting exposure to a much-larger customer base. Epocrates' network counts more than 1 million health care professionals as users, including around half of all physicians in the U.S. Currently, around 38,000 providers use athenahealth's systems. 

Another potential positive is that the clear trend in health care is toward mobile applications. Epocrates has been a longtime leader in the mobile health space, with clinical applications for smartphones and tablets. Jonathan Bush, CEO of athenahealth, stated that the company sees the opportunity "to redefine the mobile toolset for care givers."

Both of these factors were important in athenahealth's decision to buy the smaller company. Epocrates has a strong brand presence, with recognition among 90% of U.S. physicians. The acquisition could open doors for athenahealth that might otherwise have remained closed.

Also, while competitors such as Quality Systems (NASDAQ: QSII  ) have launched mobile applications, athenahealth hasn't done much in the growing area thus far. The acquisition will help the company establish a significant presence in point-of-care solutions. Its larger resources could also enable more effective competition against current Epocrates rivals, including WebMD's (NASDAQ: WBMD  ) MedScape division.

Cloudy judgment?
While the merger makes sense in several ways, one significant question remains: Did athenahealth pay too much?

Consider that while Epocrates boasts large numbers of users, most of those use only the company's free drug reference product. The company hasn't shown impressive revenue or earnings growth. In fact, only one quarter in 2012 thus far has had positive earnings.

Despite this lackluster financial performance, athenahealth is paying more than 50 times forward earnings for Epocrates. Perhaps that price is easier to pay since athenahealth looks expensive itself, with a forward P/E of nearly 64. However, the key difference is that athenahealth has grown sales at a rapid pace while Epocrates has not.

Also, athenahealth showed $180 million in total cash on its balance sheet as of the end of last quarter. The Epocrates purchase will wipe much of this out, although the exact amount depends on how much will be borrowed to finance the transaction. This leaves athenahealth in a worse position in the event that other acquisition opportunities emerge.

On the fence
The market appears to have liked the acquisition. Shares for athenahealth were up 2% at yesterday's close. I'm sitting on the fence on this one, though. The combination brings some interesting opportunities. What I don't know, however, is whether those opportunities will make enough money to offset the cost. Maybe they will, but I won't be surprised if they don't.

What's inside Supernova?
Motley Fool co-founder David Gardner spotted athenahealth as a big mover before the stock's tremendous gains of 2012. In fact, David's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 06, 2013, at 8:51 PM, georgespelvin wrote:

    athena's p/e has nothing to do with whether they paid too much for Epocrates. Athena paid with cash.

    that they paid with cash is a sign that Epocrates regarded the stock as overpriced and by any reasonable metric it is too high by twice and more reasonably by three times.

    Epocrates even in its premium version charges $10 per month. It is a rounding error compared to the revenue per doctor of Athena.

    Cross selling to its existing clients is meaningless and attempting to use it to extend the Epocrates footprint will face the same issues Epocrates faced.

    Acquisitions like this are what companies do when they are near the end of their rope.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2184508, ~/Articles/ArticleHandler.aspx, 12/21/2014 1:15:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 17,804.80 26.65 0.15%
S&P 500 2,070.65 9.42 0.46%
NASD 4,765.38 16.98 0.36%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/19/2014 4:00 PM
ATHN $139.26 Up +2.54 +1.86%
Athenahealth CAPS Rating: **
EPOC.DL $0.00 Down +0.00 +0.00%
Epocrates Inc. CAPS Rating: *****
QSII $15.63 Up +0.24 +1.56%
Quality Systems CAPS Rating: ****
WBMD $39.91 Up +0.46 +1.17%
WebMD Health Corp. CAPS Rating: **

Advertisement